A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2018-06-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259
pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms
of benefit/ risk ratio for further development in the target subject population.